+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Age-Related Macular Degeneration Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • November 2023
  • Region: Global
  • Expert Market Research
  • ID: 5921388
According to the report, the global age-related macular degeneration (AMD) market is projected to grow at a CAGR of 6.4% between 2024 and 2032 reaching a value of approximate USD 3.13 billion by 2032. Aided by the escalating global aging population and the increasing awareness of early AMD detection, the market is expected to grow significantly by 2032.

Age-related macular degeneration, commonly known as AMD, is a leading cause of vision loss in individuals aged 50 and above. It affects the macula, a tiny part of the retina responsible for sharp, central vision, gradually leading to blurred vision. While its early stages might have minimal symptoms, AMD can progress to a stage where it significantly hampers daily activities. Primarily categorised into dry (non-neovascular) and wet (neovascular) types, AMD presents a growing challenge to global health systems.

The stark rise in the aging population worldwide presents a pivotal driver for the age-related macular degeneration (AMD) market growth. As age is a significant risk factor for AMD, the expanding elderly demographic invariably translates to a heightened number of AMD cases, thereby pushing the demand for diagnostic and therapeutic solutions.

Moreover, global efforts to raise awareness about AMD and the importance of early detection have gained momentum. According to the age-related macular degeneration (AMD) market analysis, the regular eye examinations can identify the early signs of AMD, enabling timely interventions and potentially slowing the disease progression. Such awareness campaigns, often backed by governmental and non-governmental entities, have played a crucial role in driving the AMD market, as more individuals seek diagnostic consultations and treatment.

On the therapeutic front, while no cure exists for AMD, several treatments can slow its progression, especially for the wet type. The introduction of anti-VEGF agents has revolutionised the treatment landscape for neovascular AMD, offering significant vision improvements for many patients. As research intensifies, newer therapeutic agents with enhanced efficacy and fewer side effects are emerging, further propelling the market forward.

The positively influence on the age-related macular degeneration (AMD) market outlook is marked by relentless research and development. Efforts are underway to identify potential biomarkers for early AMD detection and to understand the underlying genetic and environmental factors, which could unlock preventive strategies in the future. Furthermore, as telemedicine and artificial intelligence gain traction, their integration into AMD diagnostics and monitoring promises to revolutionise patient care, offering remote, yet efficient, patient management.

Market Segmentation

The market can be divided based on product, drug, route of administration, and region.

Market Breakup by Product

  • Wet AMD
  • Dry AMD

Market Breakup by Drug

  • Lucentis
  • Eylea
  • Avastin
  • Others

Market Breakup by Route of Administration

  • Intravenous
  • Intravitreal

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the global age-related macular degeneration (AMD) market. Some of the major players explored in the report are as follows:
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)
  • Others

Table of Contents

1 Preface2 Report Coverage - Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Age-Related Macular Degeneration (AMD) Market Analysis
8.1 Key Industry Highlights
8.2 Global Age-Related Macular Degeneration (AMD) Historical Market (2018-2023)
8.3 Global Age-Related Macular Degeneration (AMD) Market Forecast (2024-2032)
8.4 Global Age-Related Macular Degeneration (AMD) Market by Product
8.4.1 Wet AMD
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Dry AMD
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.5 Global Age-Related Macular Degeneration (AMD) Market by Drug
8.5.1 Lucentis
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Eylea
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Avastin
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Others
8.6 Global Age-Related Macular Degeneration (AMD) Market by Route of Administration
8.6.1 Intravenous
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Intravitreal
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.7 Global Age-Related Macular Degeneration (AMD) Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Age-Related Macular Degeneration Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Age-Related Macular Degeneration Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Age-Related Macular Degeneration Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Age-Related Macular Degeneration Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Age-Related Macular Degeneration Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter's Five Forces Analysis
14.2.1 Supplier's Power
14.2.2 Buyer's Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Bayer AG
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 F. Hoffmann-La Roche Ltd.
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Novartis AG
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Age-Related Macular Degeneration (AMD) Market: Key Industry Highlights, 2018 and 2032
2. Global Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Product (USD Billion), 2018-2023
3. Global Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Product (USD Billion), 2024-2032
4. Global Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Drug (USD Billion), 2018-2023
5. Global Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Drug (USD Billion), 2024-2032
6. Global Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Route of Administration (USD Billion), 2018-2023
7. Global Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Route of Administration (USD Billion), 2024-2032
8. Global Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Region (USD Billion), 2018-2023
9. Global Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Region (USD Billion), 2024-2032
10. North America Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
11. North America Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Europe Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Europe Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Asia Pacific Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Asia Pacific Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Latin America Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Latin America Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Middle East and Africa Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
19. Middle East and Africa Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Global Age-Related Macular Degeneration (AMD) Market Structure

Companies Mentioned

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)

Methodology

Loading
LOADING...

Table Information